The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, comprising a compound represented by Formula (I), an enantiomer thereof a diastereomer thereof, or a pharmaceutically acceptable salt thereof.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

There is herein provided a compound of formula (I). ##STR00001##

There is herein provided a compound of formula (I). ##STR00001##

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.

An acid gas absorbent includes at least one kind of secondary amine compound represented by formula (1): ##STR00001##
where R.sup.1 is a cyclopentyl group or a cyclohexyl group which may be substituted by a substituted or non-substituted alkyl group having 1 to 3 carbon atoms, R.sup.2 and R.sup.3 each indicate an alkylene group having 2 to 4 carbon atoms, and R.sup.2 and R.sup.3 may each be the same or different, and be a straight chain or have a side chain.

A process for producing a compound of the formula (I) ##STR00001##
involves at least reacting a compound of the formula (II) ##STR00002##
with hydrogen and water in the presence of at least one homogeneous transition metal catalyst TMC 1.

A process for producing a compound of the formula (I) ##STR00001##
involves at least reacting a compound of the formula (II) ##STR00002##
with hydrogen and water in the presence of at least one homogeneous transition metal catalyst TMC 1.